Tigecycline Activity Tested Against Rarely Recovered Gram-positive Species

**RESULTS**

- Isolates were recovered predominantly from bacteremias (57.1%) and SSSI (42.9%).

- Tigecycline was active against the majority of isolates, with MIC values ranging from ≤0.03 to ≥0.12 µg/ml.

- The highest tigecycline MIC was only 1 µg/ml, observed in only two strains (0.11%).

- One antimicrobial (spp.) was tested against strains of Staphylococcus aureus and coagulase-negative Staphylococci.

- Tigecycline showed potent in vitro activity against many rarely recovered Gram-positive species.

- 99.5% of strains were inhibited at tigecycline concentrations of 0.06-0.25 µg/ml.

**CONCLUSIONS**

- Tigecycline showed potential in vitro activity against many rarely recovered Gram-positive pathogens.

- The results of this study indicated that tigecycline may have an important role in the treatment of infections caused by these species as guided by reference MIC test results.

**ACKNOWLEDGMENT**

This study was supported by a research grant from Pfizer, Inc.

**REFERENCES**

- Livermore DM (2005) 

**TABLES**

<table>
<thead>
<tr>
<th>Agent</th>
<th>MIC50 (µg/ml)</th>
<th>MIC90 (µg/ml)</th>
<th>Range</th>
<th>CLSI</th>
<th>EUCAST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levofloxacin</td>
<td>≤0.12</td>
<td>≤0.25</td>
<td>0.015-0.25</td>
<td>≤0.12</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Linezolid</td>
<td>≤0.06</td>
<td>≤0.25</td>
<td>0.015-0.25</td>
<td>≤0.06</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Amoxicillin/clavulanate</td>
<td>≤0.12</td>
<td>≤0.25</td>
<td>0.06-0.25</td>
<td>≤0.12</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Cefepime</td>
<td>≤0.06</td>
<td>≤0.25</td>
<td>0.03-0.25</td>
<td>≤0.06</td>
<td>≤0.25</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>≤0.25</td>
<td>≤0.5</td>
<td>0.06-0.5</td>
<td>≤0.25</td>
<td>≤0.5</td>
</tr>
</tbody>
</table>

**FIGURE**

- **Table 2** Activity of Tigecycline and comparator antimicrobial agents tested against uncommonly isolated species.

- **Table 1** MIC distribution of tigecycline tested against rarely recovered Gram-positive clinical isolates collected as part of the SENTRY Antimicrobial Surveillance Program (2001-2006).

**DISCUSSION**

- Tigecycline possesses a proven broad-spectrum of activity against numerous bacterial pathogens, including aerobic and anaerobic species. Tigecycline is approved in the United States for treatment of infections caused by these species as guided by reference MIC test results.